肿瘤细胞治疗研究
英文原题：Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases.
Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Daratumumab 是一种首创的人源抗 CD38 IgG1 单克隆抗体，已获批用于治疗新诊断和复发难治性多发性骨髓瘤。临床前数据支持 daratumumab 能够清除产生自身抗体的浆细胞、B 细胞和 NK 细胞。这些报告显示，使用 daratumumab 治疗对多线治疗难治的自身免疫性疾病具有前景，这鼓励了在多种对标准治疗难治的自身免疫性疾病中使用 daratumumab。本综述旨在总结报告使用抗 CD38 抗体治疗血液系统自身免疫性疾病经验的文献，重点关注最常见的自身免疫性血液病，包括自身免疫性溶血性贫血、免疫性血小板减少症、移植后血细胞减少症和纯红细胞再生障碍。
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for treating newly diagnosed and relapsed refractory multiple myeloma. Pre-clinical data supported daratumumab's ability to deplete autoantibodies producing plasma cells, B-cells, and NK cells. Those reports showed promising results on using daratumumab in autoimmune disorders that are refractory to multiple lines of therapies, which encouraged using daratumumab in various autoimmune conditions that are refractory to standard therapies.
This review aims to summarize the literature reporting experience using anti-CD38 antibodies in hematological autoimmune diseases, focusing on the most common autoimmune hematological diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, post-transplant cytopenia, and pure red blood cell aplasia.
MEMBER ACCOUNT
登录成功会直接打开下一页。
